Cargando…

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway

Tumor metastasis is the most lethal and debilitating process that threatens cancer patients. Among the regulators involved in tumor metastasis, lysyl oxidase (LOX) is an important contributor for tumor invasion, migration and the formation of the pre-metastatic niche. Although the relationship betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Xiaoying, Du, Hongzhi, Quan, Xingping, Shi, Lei, Zhang, Qianqian, Wu, Yao, Liu, Yang, Xiao, Jing, Li, Yong, Lu, Ligong, Ai, Xun, Zhan, Meixiao, Yuan, Shengtao, Sun, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809401/ https://www.ncbi.nlm.nih.gov/pubmed/29472856 http://dx.doi.org/10.3389/fphar.2018.00021

Ejemplares similares

PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC
por: Du, Hongzhi, et al.
Publicado: (2017)

Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells
por: Hou, Xiaoying, et al.
Publicado: (2022)

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Jiang, Lei, et al.
Publicado: (2023)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
por: Zhang, Yuhan, et al.
Publicado: (2021)

Sepiapterin reductase: Characteristics and role in diseases
por: Wu, Yao, et al.
Publicado: (2020)

Silibinin Regulates Lipid Metabolism and Differentiation in Functional Human Adipocytes
por: Barbagallo, Ignazio, et al.
Publicado: (2016)

Novel Quinoline Compound Derivatives of NSC23925 as Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance
por: Quan, Xingping, et al.
Publicado: (2019)

The Effect of Silibinin on Protein Expression Profile in White Adipose Tissue of Obese Mice
por: Wang, Fei, et al.
Publicado: (2020)

Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling
por: Wei, Xiaohui, et al.
Publicado: (2019)

Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma
por: Guo, Shuai, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway
por: Bai, Yang, et al.
Publicado: (2022)

Silibinin alleviates intestinal inflammation via inhibiting JNK signaling in Drosophila
por: Yan, La, et al.
Publicado: (2023)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
por: Liu, Yaming, et al.
Publicado: (2021)

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
por: Song, Xiaotong, et al.
Publicado: (2023)

PET/CT Based EGFR Mutation Status Classification of NSCLC Using Deep Learning Features and Radiomics Features
por: Huang, Weicheng, et al.
Publicado: (2022)

Pharmacological screening of silibinin for antischizophrenic activity along with its acute toxicity evaluation in experimental animals
por: Ain, Qurat Ul, et al.
Publicado: (2023)

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China
por: Wang, Zhiqiang, et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System
por: Heeke, Simon, et al.
Publicado: (2021)

Targeted delivery of silibinin via magnetic niosomal nanoparticles: potential application in treatment of colon cancer cells
por: Shafiei, Golchin, et al.
Publicado: (2023)

Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis Partly by Inhibiting the Expression of LOX and LOXL-2
por: Tong, Xiang, et al.
Publicado: (2021)

Silibinin Induces G2/M Cell Cycle Arrest by Activating Drp1-Dependent Mitochondrial Fission in Cervical Cancer
por: You, Yanting, et al.
Publicado: (2020)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
por: Shen, Gang, et al.
Publicado: (2021)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner
por: Wu, Yao, et al.
Publicado: (2020)

Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC
por: Che, Ting-Fang, et al.
Publicado: (2015)

Celastrol Attenuates Lipid Accumulation and Stemness of Clear Cell Renal Cell Carcinoma via CAV-1/LOX-1 Pathway
por: Zhang, Chan-Juan, et al.
Publicado: (2021)

Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
por: Liu, Ying, et al.
Publicado: (2020)

Camellia nitidissima Chi Extract Potentiates the Sensitivity of Gastric Cancer Cells to Paclitaxel via the Induction of Autophagy and Apoptosis
por: He, Xu, et al.
Publicado: (2019)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
por: Hou, Xiaoying, et al.
Publicado: (2021)

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
por: Zhou, Kexun, et al.
Publicado: (2023)

miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1
por: Hua, Shengni, et al.
Publicado: (2019)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
por: Wang, Yuntao, et al.
Publicado: (2022)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis
por: Ouyang, Wen, et al.
Publicado: (2020)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer
por: Addeo, Raffaele
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ka78hp0fl6doqh3rvmrgkf0tim